The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

This evaluation reviews the evidence for osimertinib for treating NSCLC after complete tumour resection. It also reviews new evidence collected as part of the managed access agreement, which includes ...